

# Is now the time for probiotics in diabetes management?

Barbara Idzior-Waluś, Małgorzata Waluś-Miarka

Department of Metabolic Diseases, Jagiellonian University Medical College, Kraków, Poland

Type 2 diabetes mellitus, a chronic progressive metabolic disease, has reached the proportions of an epidemic in the past 30 years, with worldwide prevalence approaching 400 million people. The epidemic is largely secondary to overnutrition and sedentary lifestyle, leading to highly prevalent overweight and obesity, which contribute to the development of type 2 diabetes.<sup>1</sup>

Patients with metabolic syndrome and abnormal fat distribution, with the expansion of visceral fat, have elevated plasma proinflammatory markers, prothrombotic state, and vascular dysfunction. These abnormalities contribute causally to the development of metabolic disorders observed in patients with central obesity.<sup>2,3</sup>

In recent years, considerable evidence has been gathered on the effect of gut microbiota composition as a potential factor affecting the energy balance and contributing to fat accumulation. The gut microbiota are one of the most important determinants of metabolic disorders such as obesity, insulin resistance, and type 2 diabetes with related comorbidities. There is an increasing number of studies exploring the effects of probiotic bacterial strains in the prevention or treatment of metabolic and cardiovascular risk factors.<sup>4,5</sup> The gut microbiota is affected by a complex interaction between the host's genetics and environment; however, diet is one of the main factors affecting intestinal bacterial composition.

The "western" diet, rich in saturated/trans fats and simple sugars and poor in fibers, is associated with the alteration of bacterial population, leading to disruption of intestinal barrier, activation of proinflammatory mechanisms, and metabolic endotoxemia. In consequence, this leads to excessive internal diffusion of bacterial fragments/products, which promotes inflammation in key insulin-responsive tissues, resulting in insulin resistance.<sup>6-8</sup>

There are several approaches to modifying the colonic flora and manipulating the intestinal

microbiota, namely, the use of prebiotics, probiotics, and fecal microbial transplants.<sup>4,5,7,8</sup>

Prebiotics are defined as a selectively fermented ingredients that result in specific changes to the composition and activity of the gastrointestinal microbiota, and mainly increase the number of bifidobacteria, thus conferring a health benefit on the host. Prebiotics are nondigestible polysaccharides that promote the production of short-chain fatty acids and the growth of beneficial gut bacteria, especially *Bifidobacterium* and *Lactobacillus*. Substrates accepted as prebiotics include fructans (inulin) and fructo-oligosaccharides, galacto-oligosaccharides, and lactulose. Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Most currently used probiotics belong to bifidobacteria, lactic acid bacteria, most of them phylum Firmicutes, dairy propionibacteria, yeasts (*Saccharomyces boulardii*), *Bacillus*, and the gram-negative *Escherichia coli* strain Nissle 1917.<sup>6-8</sup>

The dietary prebiotics affect total energy intake, body weight, peptide YY and glucagon-like peptide-1 concentrations, gastric emptying times, insulin sensitivity, lipids, and inflammatory markers and immune function, although their effects were contradictory. Dietary prebiotic consumption was found to be associated with subjective improvements in satiety and reductions in postprandial glucose and insulin concentrations.<sup>4,5,9</sup>

Probiotic treatment aiming at modifying the colonic flora is thought to produce benefit for several reasons: 1) the intestinal bacterial flora favors the digestion and absorption of nutrients; 2) gut microbiota is related to overall immunity of the host; and 3) microbiome may alter the synthesis of intestinal hormones such as glucagon-like peptide 1 and influences the host metabolism.<sup>4,5,8,10,11</sup>

Probiotics are able to decrease metabolic endotoxemia by restoring the disrupted intestinal mucosal barrier. There is the perspective of using new bacterial strains, such as butyrate-producing

## Correspondence to:

Prof. Barbara Idzior-Waluś, MD,  
PhD, Katedra i Klinika Chorób  
Metabolicznych, Uniwersytet  
Jagielloński, Collegium Medicum,  
ul. Kopernika 15, 31-501 Kraków,  
Poland, phone: +48 12 424 83 01,  
fax: +48 12 421 97 86,  
e-mail: mmwalus@cyf-kr.edu.pl  
Received: November 24, 2015.  
Accepted: November 24, 2015.  
Conflict of interest: none declared.  
Pol Arch Med Wewn. 2015;  
125 (11): 797-798  
Copyright by Medycyna Praktyczna,  
Kraków 2015

bacteria and the mucolytic *Akkermansia muciniphila*, as well as prebiotics to enhance the functionality of probiotics.

In the current issue of *Pol Arch Med Wewn*, Kasińska and Drzewoski,<sup>12</sup> in their article, assessed the effect of probiotic supplementation on selected modifiable cardiometabolic risk factors in type 2 diabetes by a meta-analysis of existing research. The authors carefully planned the material included in the meta-analysis (reviewed articles in PubMed, Embase, Cochrane Library, and Scopus databases and searched the databases using the terms “probiotics” and “diabetes”). They included only full-text articles published in English on randomized controlled trials (RCTs) including adult patients with diagnosed type 2 diabetes. Eventually, 8 RCTs involving 438 subjects were included in the meta-analysis.

A pooled analysis of 3 RCTs showed a significant decrease in the level of hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) in diabetic patients consuming probiotics compared with those consuming placebo (standardized mean difference [SDM], -0.81; confidence interval [CI], -1.33 to -0.29;  $P = 0.0021$ ) and also 3 RCTs demonstrated a significant decrease of HOMA-IR after consumption of probiotics vs placebo (SMD, -2.10; CI, -3.00 to -1.2,  $P < 0.0001$ ;  $I^2 = 82.91\%$ ;  $P = 0.0029$  for heterogeneity). In the meta-analysis, supplementation with probiotics was not found to alter the lipid profile or the levels of fasting glucose, insulin, or C-reactive protein.

Overall, the results of the meta-analysis are important for the treatment of patients with type 2 diabetes. The use of probiotics has been shown to significantly improve long-term glycemic control, measured by HbA<sub>1c</sub> levels and insulin resistance, assessed by the HOMA-IR. These effects could potentially inhibit the progression of the disease and hamper the development of its chronic complications. Finally, the use of well-studied probiotic species is safe, and they are generally well tolerated.<sup>13</sup>

A meta-analysis allows to combine individual small trials to improve the power to detect the direction, size, and consistency of an effect. It is necessary to use a meta-analysis to synthesize the results of RCTs into recommendations for clinicians. The results of this meta-analysis are important for the treatment of diabetes and prevention of macro- and microvascular complications. However, the main limitation of this meta-analysis is a lack of subgroup analysis for specific species/strains or species combination on metabolic parameters. The different probiotic species/strains used in clinical trials in different doses will likely affect their clinical efficacy in type 2 diabetes patients. Therefore, synthesizing the data from different interventions may in part be responsible for the significant heterogeneity observed in the current meta-analysis. Some authors recommend that all future meta-analyses of probiotics, in any clinical setting, should include subgroup

analyses on specific species/strains and specific combinations.<sup>14</sup>

Metabolic disorders, such as obesity, diabetes, and cardiovascular disease, are widespread in industrialized societies. The concept that manipulating the gut microbiota, which influences metabolic diseases to improve host metabolism, has gained a considerable interest in recent years. Currently, several potential bacterial species have been identified, and novel mechanisms of action influencing their beneficial effects have been elucidated. The new treatment option is incorporation of genetically modified bacteria that secrete molecules into the intestinal microbiota to provide sustained treatment. The genetically modified bacteria are capable of producing sufficient amounts of secreted small molecules to induce significant therapeutic effects on the target organ outside the intestinal tract.<sup>15</sup>

## REFERENCES

- 1 Nathan DM. Diabetes: advances in diagnosis and treatment. *JAMA*. 2015; 8; 314: 1052-1062.
- 2 DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care*. 1991; 14: 173-194.
- 3 Febbraio MA. Role of interleukins in obesity: implications for metabolic disease. *Trends Endocrinol Metab*. 2014; 25: 312-319.
- 4 Le Barz M, Anhe FF, Varin TV, et al. Probiotics as complementary treatment for metabolic disorders. *Diabetes Metab J*. 2015; 39: 291-303.
- 5 Delzenne NM, Cani PD, Everard A, et al. Gut microorganisms as promising targets for the management of type 2 diabetes. *Diabetologia*. 2015; 58: 2206-2217.
- 6 Khan MT, Nieuwdorp M, Backhed F. Microbial modulation of insulin sensitivity. *Cell Metab*. 2014; 20: 753-760.
- 7 Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes*. 2008; 57: 1470-1481.
- 8 Scott KP, Antoine JM, Midtvedt T, van Hemert S. Manipulating the gut microbiota to maintain health and treat disease *Microb Ecol Health Dis*. 2015; 26: 25877.
- 9 Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. *Br J Nutr*. 2014; 111: 1147-1161.
- 10 Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance *Mol Aspects Med*. 2013; 34: 39-58.
- 11 Vrieze A, Holleman F, Zoetendal EG, et al. The environment within: how gut microbiota may influence metabolism and body composition. *Diabetologia*. 2010; 53: 606-613.
- 12 Kasińska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a meta-analysis. *Pol Arch Med Wewn*. 2015; 125: 803-813.
- 13 Sanders ME, Akkermans LM, Haller D, et al. Safety assessment of probiotics for human use. *Gut Microbes*. 2010; 1: 164-185.
- 14 Whelan K. Editorial: The importance of systematic reviews and meta-analyses of probiotics and prebiotics. *Am J Gastroenterol*. 2014; 109: 1563-1565.
- 15 Chen Z, Guo L, Zhang Y, et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. *J Clin Invest*. 2014; 124: 3391-3406.